Sun Pharmaceutical Industries will purchase Taro’s outstanding shares for $43 each, which will total $348 million.
Sun Pharma and Taro Reach Definitive Merger Agreement
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours